Synapse

← Ron Dagan

Papers by Ron Dagan

Page 1 · newest first

  1. Determination of neutron radiation fields and exposure in geological repositories for high-level spent-fuel radioactive wasteDiscover Applied Sciences · 2026
  2. Is the Interplay Between Maternal Tdap and Pneumococcal Conjugate Vaccines Relevant to Infant Pneumococcal Carriage?The Journal of Infectious Diseases · 2026
  3. The 0E2 benchmarks for PWR UO 2 decay heat: an analysis from the NEA WPNCSEPJ Nuclear Sciences & Technologies · 2026
  4. Differential Impact of Pneumococcal Conjugate Vaccines on Hospitalized Versus Outpatient Community-Acquired Alveolar Pneumonia in Children Younger Than 5 Years Suggests Differences in PathogenesisOpen Forum Infectious Diseases · 2025
  5. Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in childrenExpert Review of Anti-infective Therapy · 2025
  6. Decline in Community-Acquired Alveolar Pneumonia Positive for Respiratory Syncytial Virus in Hospitalized Children Following Implementation of Pneumococcal Conjugate Vaccine (PCV) in IsraelClinical Infectious Diseases · 2025
  7. Estimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal ColonizationThe Journal of Infectious Diseases · 2025
  8. Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine Is Reduced in Infants Immunized During the Respiratory Viral SeasonClinical Infectious Diseases · 2024
  9. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysisThe Lancet Infectious Diseases · 2024
  10. Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysisThe Lancet Infectious Diseases · 2024
  11. Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)Clinical Infectious Diseases · 2024
  12. Estimating the serotype-specific association between the concentration of vaccine-induced serum antibodies and protection against pneumococcal colonization2024
  13. Geographical migration and fitness dynamics of Streptococcus pneumoniaeNature · 2024
  14. Estimating geographical spread of Streptococcus pneumoniae within Israel using genomic dataMicrobial Genomics · 2024
  15. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV SeasonJournal of the Pediatric Infectious Diseases Society · 2024
  16. An introduction to Spent Nuclear Fuel decay heat for Light Water Reactors: a review from the NEA WPNCSEPJ Nuclear Sciences & Technologies · 2024
  17. The impact of pneumococcal conjugate vaccine on ceftriaxone consumption in the community among young childrenInternational Journal of Infectious Diseases · 2023
  18. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trialsNature Communications · 2023
  19. Dynamics of invasive pneumococcal disease in infants < 2 years old following PCV7/13 implementation using two infant and a booster dose schedule: evidence for indirect protection of young infants, Israel, 2004 to 2019Eurosurveillance · 2023
  20. A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)Clinical Infectious Diseases · 2023
  21. Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyPEDIATRICS · 2023
  22. Prioritising respiratory syncytial virus prevention in low-income and middle-income countriesThe Lancet Global Health · 2023
  23. Nirsevimab for Prevention of RSV in Term and Late-Preterm InfantsNew England Journal of Medicine · 2023
  24. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIVAIDS · 2023
  25. A Hypothesis-Generating Prospective Longitudinal Study to Assess the Relative Contribution of Common Respiratory Viruses to Severe Lower Respiratory Infections in Young ChildrenThe Pediatric Infectious Disease Journal · 2023
  26. The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective studyEBioMedicine · 2023
  27. Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)Vaccine · 2023
  28. Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factorsHuman Vaccines & Immunotherapeutics · 2023
  29. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Vaccine · 2023
  30. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) studyBlood Advances · 2022
  31. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)Vaccine · 2022
  32. The COVID-19 Pandemic as an Opportunity for Unravelling the Causative Association between Respiratory Viruses and Pneumococcus-Associated Disease in Young Children: A Prospective Study2022
  33. Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing studyThe Lancet Microbe · 2022
  34. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19–Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021JAMA Network Open · 2022
  35. The Pneumococcus–Respiratory Virus Connection—Unexpected Lessons From the COVID-19 PandemicJAMA Network Open · 2022
  36. Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care FacilitiesJAMA Internal Medicine · 2022
  37. The Effect of Macrolides on Mortality in Bacteremic Pneumococcal Pneumonia: A Retrospective, Nationwide Cohort Study, Israel, 2009–2017Clinical Infectious Diseases · 2022
  38. A Streptococcus pneumoniae lineage usually associated with pneumococcal conjugate vaccine (PCV) serotypes is the most common cause of serotype 35B invasive disease in South Africa, following routine use of PCVMicrobial Genomics · 2022
  39. International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal diseaseVaccine · 2022
  40. Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)Open Forum Infectious Diseases · 2021
  41. Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort StudyClinical Infectious Diseases · 2021
  42. Emergence of a multidrug resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV132021
  43. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIVAIDS · 2021
  44. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)Human Vaccines & Immunotherapeutics · 2021
  45. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort StudyClinical Infectious Diseases · 2021
  46. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)Vaccine · 2021
  47. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)Vaccine · 2021
  48. Decline in pneumococcal disease in young children during the COVID-19 pandemic associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: A prospective cohort study2021
  49. Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective SurveillanceClinical Infectious Diseases · 2021
  50. The role of interspecies recombination in the evolution of antibiotic-resistant pneumococcieLife · 2021